News on Xenometrix GmbH from BioPortfolio.com http://www.BioPortfolio.com Consolidated Xenometrix GmbH news from BioPortfolio.com Wed, 10 Feb 2010 15:18:30 GMT en Mycobacteria: Findings in mycobacteria reported from Schulke & Mayr GmbHhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041193&HITNO=0&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041193&THISHREF=http://c.moreover.com/click/here.pl%3fz2539026555%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041193&HITNO=0&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041193&THISHREF=http://c.moreover.com/click/here.pl%3fz2539026555%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Kamada Announces Enrollment Of First Patient In Its Pivotal Study For Inhaled AAT In Europehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039685&HITNO=1&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039685&THISHREF=http://c.moreover.com/click/here.pl%3fz2538321789%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039685&HITNO=1&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039685&THISHREF=http://c.moreover.com/click/here.pl%3fz2538321789%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: Report on market potential for RNA therapieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042593&HITNO=2&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042593&THISHREF=http://c.moreover.com/click/here.pl%3fz2539469163%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042593&HITNO=2&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042593&THISHREF=http://c.moreover.com/click/here.pl%3fz2539469163%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharmahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042495&HITNO=3&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042495&THISHREF=http://c.moreover.com/click/here.pl%3fz2539436667%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042495&HITNO=3&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042495&THISHREF=http://c.moreover.com/click/here.pl%3fz2539436667%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharmahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042355&HITNO=4&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042355&THISHREF=http://c.moreover.com/click/here.pl%3fz2539400452%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042355&HITNO=4&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042355&THISHREF=http://c.moreover.com/click/here.pl%3fz2539400452%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEarthtimes.org: Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharmahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042328&HITNO=5&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042328&THISHREF=http://c.moreover.com/click/here.pl%3fz2539386355%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042328&HITNO=5&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042328&THISHREF=http://c.moreover.com/click/here.pl%3fz2539386355%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comRBC Dain Rauscher: Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharmahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042326&HITNO=6&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042326&THISHREF=http://c.moreover.com/click/here.pl%3fz2539386015%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042326&HITNO=6&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042326&THISHREF=http://c.moreover.com/click/here.pl%3fz2539386015%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBusiness Wire via Yahoo!: Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharmahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042273&HITNO=7&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042273&THISHREF=http://c.moreover.com/click/here.pl%3fz2539369382%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042273&HITNO=7&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042273&THISHREF=http://c.moreover.com/click/here.pl%3fz2539369382%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharmahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042214&HITNO=8&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042214&THISHREF=http://c.moreover.com/click/here.pl%3fz2539361221%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042214&HITNO=8&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042214&THISHREF=http://c.moreover.com/click/here.pl%3fz2539361221%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBusiness Wire: Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharmahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042212&HITNO=9&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042212&THISHREF=http://c.moreover.com/click/here.pl%3fz2539361205%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042212&HITNO=9&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042212&THISHREF=http://c.moreover.com/click/here.pl%3fz2539361205%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBusiness Wire UK: Boehringer Ingelheim to make Japanese drug maker SSP 100% subsidiaryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041413&HITNO=10&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041413&THISHREF=http://c.moreover.com/click/here.pl%3fz2539099311%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041413&HITNO=10&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041413&THISHREF=http://c.moreover.com/click/here.pl%3fz2539099311%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comKyodo: Daiichi Sankyo's subsidiary seeks approval for Alzheimer's type Dementia treatment in Japanhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039734&HITNO=11&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039734&THISHREF=http://c.moreover.com/click/here.pl%3fz2538348937%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039734&HITNO=11&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039734&THISHREF=http://c.moreover.com/click/here.pl%3fz2538348937%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: ALIUD Pharma GmbH-Company Report - new market report releasedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037799&HITNO=12&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037799&THISHREF=http://c.moreover.com/click/here.pl%3fz2537289098%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037799&HITNO=12&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037799&THISHREF=http://c.moreover.com/click/here.pl%3fz2537289098%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: Kamada Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037052&HITNO=13&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037052&THISHREF=http://c.moreover.com/click/here.pl%3fz2536879771%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037052&HITNO=13&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037052&THISHREF=http://c.moreover.com/click/here.pl%3fz2536879771%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPipelineReview: Hepatitis C Virus: Research in the area of hepatitis C virus reported from Boehringer Ingelheim GmbH, Department of Biological Scienceshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033358&HITNO=14&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033358&THISHREF=http://c.moreover.com/click/here.pl%3fz2535162672%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033358&HITNO=14&MSIZE=385&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xenometrix%20GmbH&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033358&THISHREF=http://c.moreover.com/click/here.pl%3fz2535162672%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: